Jump to content

Wang Qunbin

The comprehensive free global encyclopedia of CEOs, corporate leadership, and business excellence
Wang Qunbin
Wang Qunbin
Born1969 (age 57–56)
NationalityChinese
EducationFudan University (BSc, genetic engineering, 1991)
OccupationBusinessman
CompanyFosun International
TitleExecutive Director and Co-Chairman, Fosun International

Wang Qunbin (汪群斌; born 1969) is a Chinese businessman and one of the four founders of the Shanghai-based conglomerate Fosun International. Wang has been an executive director and co-chairman of the company since February 21, 2020, serving alongside its chairman, Guo Guangchang. Wang was the group's chief executive officer from March 28, 2017, to February 21, 2020, and before that its president from January 2009.[1][2]

A genetic engineering graduate of Fudan University, Wang taught at the university's Genetic Research Institute before joining the business he and his classmates had started. In the 1990s he led the team that developed PCR diagnostic reagents, the product that earned the business its first RMB100 million. Wang then ran the group's pharmaceutical arm, Shanghai Fosun Pharmaceutical, as general manager and later chairman from 1995 until June 2010.[3][4]

As president and chief executive, Wang oversaw the group's expansion into insurance and its overseas acquisitions, and he chaired the Hong Kong reinsurer Peak Reinsurance until July 2018. While Wang was chief executive, the group's annual revenue grew from RMB73.97 billion in 2016 to RMB142.98 billion in 2019.[5][1] As co-chairman, he has described his work as supporting Guo on top-level design, strategy and team building, and he has said he spends more than half his time on people and organisation.[6][3]

Wang holds 14.71 percent of Fosun International Holdings, the company through which Guo controls about 72.78 percent of Fosun International, so he is the second-largest owner of the group's controlling shareholder.[7] Forbes listed him as a billionaire 11 times, most recently with an estimated net worth of US$1.2 billion in April 2021.[8]

Early life and education

Wang Qunbin was born in 1969.[8] In a letter to shareholders in Fosun's 2017 annual report, Guo Guangchang wrote that he himself came from a village in Dongyang, Zhejiang province, and that "Ah Wang (Wang Qunbin, CEO of the Company) also came from a village but his family was slightly better off than mine". Guo wrote that both were admitted to Fudan University "due to our hard work", and credited education as the most important factor that changed their lives.[5]

Wang entered Fudan's life sciences programme as part of the class of 1987.[9] Wang received a bachelor's degree in genetic engineering from the university in 1991.[10] Before joining the business Wang worked as a lecturer at Fudan's Genetic Research Institute.[2] Liang Xinjun, another of the group's founders, studied in Fudan's genetic engineering department from September 1987 to July 1991, the same years as Wang.[11]

Career

Founding years

Guo Guangchang and several Fudan classmates set up the business that became Fosun, Shanghai Guangxin Technology Development, in 1992.[11] Wang has described the founding team of four as having started with 38,000 yuan.[12] Company filings list the four founders as Guo, Liang Xinjun, Wang and Fan Wei. When the company listed in 2007 they held 58 percent, 22 percent, 10 percent and 10 percent respectively of Fosun International Holdings, the top holding company.[13]

National Business Daily, in a 2020 profile, reported that in the 1990s Wang led the team that developed PCR diagnostic reagents, which brought the company its first RMB100 million.[3] Wang has been a director of Fosun Group, later called Fosun High Technology, since it was established in November 1994.[2][14] He stepped down from that board on November 8, 2017.[5]

Fosun Pharma, 1995 to 2010

Wang Qunbin was a director and general manager of Shanghai Fosun Pharmaceutical (Fosun Pharma) from 1995, when its predecessor Shanghai Fosun Industrial was set up, until October 2007. In October 2007 he became chairman of Fosun Pharma.[2] Wang stepped down as chairman in June 2010 but stayed on the board.[4]

According to a 2012 profile in the Chinese edition of the Harvard Business Review, Wang spent 13 years in total as president and chairman of Fosun Pharma, from its Shanghai listing in 1998 to 2010. The magazine reported that the company's net profit rose more than tenfold in that time, a compound annual growth rate above 29 percent. Wang credited benchmarking against companies such as Johnson & Johnson, and the differentiated strategy that came out of it.[15]

During these years Wang also held positions in China's pharmaceutical industry. The group's 2009 annual report listed Wang as chairman of the Shanghai Biopharmaceutics Industry Association and vice chairman of the China Pharmaceutical Industry Association. It also recorded that he had been named one of the "Top Ten Professional Managers in China Pharmaceutical Industry in 2004".[2] He was a non-executive director of the drug distributor Sinopharm from January 2003, and became its vice chairman in June 2010.[4] He was also a director of the Shanghai-listed retailer Shanghai Friendship Group from September 2000 to June 2010.[4]

Fosun International director and president, 2007 to 2017

Fosun International listed on the Main Board of the Hong Kong Stock Exchange on July 16, 2007. Wang was one of its executive directors at the listing.[13] Wang was appointed president of the company in January 2009.[2]

In a speech to the Sohu Entrepreneurs Forum in November 2010, Wang said the group's assets had passed RMB103 billion by mid-2010. He described the 2010 investment in the French resort company Club Med as an opportunity created by the European debt crisis, and said the group aimed to invest in established brands in Europe, the United States and Japan and develop them using China's strengths. Wang also referred to John Snow, the former United States Treasury Secretary, having become an adviser to the Fosun board that year.[12] In the 2012 Harvard Business Review China profile, Wang said he wanted employees to think like entrepreneurs and not worry about reporting past their immediate superiors, and that independent directors should never be "vases", or decoration. The magazine reported that by then he was concentrating on the overall management of the group, which had set itself the goal of managing a trillion yuan of assets within ten years.[15]

Fosun moved into insurance in this period and Wang took several of the board seats. Wang became chairman of Peak Reinsurance, a Hong Kong reinsurer backed by the group, and in a 2013 interview with Insurance Insight he described the group as "an insurance-oriented investment group".[16][17] The 2013 annual report also listed him as chairman of Forte, the group's property company, and as a director of the steelmaker Nanjing Nangang and of Henan Lingrui Pharmaceutical.[16] After the group acquired control of the Portuguese insurers in 2014, Wang joined the boards of Fidelidade, Multicare and Cares. That year he also sat on the boards of Yuyuan and Forte and was a non-executive director of ROC.[18]

Insurance Business magazine included Wang in its "Hot 100" list for 2016. It noted that the group had raised US$1.5 billion to fund acquisitions in 2015 and had bought American insurers including Meadowbrook and Ironshore, where Wang was a director.[19] The 2016 annual report recorded that the group held 100 percent of both Ironshore and Meadowbrook (MIG) by then.[20]

Chief executive officer, 2017 to 2020

On the night of March 28, 2017, Liang Xinjun, who had been the group's chief executive, told staff that he was resigning from management and the board for health reasons. The company named Wang chief executive with immediate effect, and made Chen Qiyu and Xu Xiaoliang co-presidents.[11] The 2017 annual report confirmed that Liang held the post until March 28, 2017, and that Wang was re-designated chief executive on the same date.[5]

The group's results grew during Wang's first year as chief executive. Revenue rose from RMB73.97 billion in 2016 to RMB88.03 billion in 2017, and profit attributable to owners of the parent rose from RMB10.27 billion to RMB13.16 billion.[5] The group said it made more than 100 investments and more than 50 divestments that year.[5] A recurring theme of his tenure was operational improvement. The 2017 annual report pictured Wang speaking at a Lean Six Sigma management conference on November 30, 2017, and reported that the group's Lean Six Sigma projects had produced direct economic benefits of more than RMB100 million and trained 69 black belts.[5]

In 2018 the tourism business Fosun Tourism Group was spun off and listed on the Hong Kong Stock Exchange in December. Its revenue rose 37.9 percent that year to RMB16.27 billion.[21] In 2019, Wang's last full year as chief executive, group revenue reached RMB142.98 billion and profit attributable to owners of the parent RMB14.80 billion, up about 10.4 percent on 2018. Total assets were RMB715.68 billion at the end of 2019.[1]

In late January 2020, as COVID-19 spread in China, Fosun began a global medical supplies programme on January 24. The 2019 annual report said a global allocation working group was set up "under the direct supervision of Chairman Guo Guangchang and Co-Chairman Wang Qunbin". The group built a procurement network covering 23 countries, and its first urgent purchase of 50,000 protective suits from Germany reached Shanghai four days after being bought.[1]

Co-chairman, 2020 to present

With effect from February 21, 2020, Wang Qunbin was re-designated co-chairman of Fosun International and ceased to be chief executive. Chen Qiyu and Xu Xiaoliang became co-chief executives, and Gong Ping became chief financial officer.[22][23] Guo described the changes in his letter to shareholders as "our first round of management evolution".[1]

On an investor call on February 23, 2020, Guo said neither he nor Wang was "retreating to the second line", and that the two would act as each other's "A and B roles". Wang said the group's strategic focus was now deep industrial operation, and that as co-chairman he would help Guo strengthen top-level design, strategy-setting and team development.[6]

In a September 2020 interview with National Business Daily, Wang said Fosun's industrial and global footprint was "basically complete". In principle the group would enter no new regional markets and few new industries, and would concentrate on running what it already owned for family consumers under the headings "health, happiness and wealth". He described the stock market's valuation of the group as "discounted" and said the group's balance sheet was "very healthy". Moody's had cut Fosun's corporate family rating from Ba2 to Ba3 in July 2020, and Wang said the downgrade reflected global economic concerns and had not affected the group's financing. Wang also discussed the BioNTech COVID-19 vaccine that Fosun Pharma had licensed for China, saying its price would be set by the state.[3]

Fosun International's board continued to list Wang as co-chairman through 2025 and 2026.[24][7] Wang attended all 13 board meetings held in 2025.[24] On March 13, 2026, he attended, with Guo, the signing of Fosun's third strategic cooperation agreement with HSBC China at the Bund Finance Center in Shanghai.[25] At the company's 2026 interim results presentation in Hong Kong on August 28, 2026, the first it had held there in six years, Wang said the group remained committed to streamlining its businesses and focusing on core operations. He said the group aimed to improve its credit rating step by step towards investment grade and to concentrate on insurance and the industries where it was strongest.[26] For the six months to June 30, 2026, the company reported revenue of RMB86.96 billion and profit attributable to owners of the parent of RMB1.72 billion, against RMB661.2 million a year earlier.[7]

Leadership and management style

National Business Daily described Wang Qunbin in 2020 as rarely giving interviews. It called him steady and reserved, in contrast to Guo, a confident public speaker, and said he seldom expanded on a topic unprompted. Wang described a division of labour with Guo: "When Guo does more of the external work, I do less... on strategy, Guo thinks more; on the organisational and execution side, I pay more attention. We are more like a team."[3]

After becoming co-chairman, Wang said he spent more than 50 percent of his time on people and organisation. He took part in the interviews of almost all newly promoted staff at managing director level and above, and met some senior recruits several times.[3] Wang named three qualities he looked for in hires: entrepreneurial spirit, ability to learn, and not being constrained by past experience. Under the internal "competition and cooperation" system introduced in 2020, every business was ranked on a "271" basis. The top 20 percent received extra incentives and resources, and the bottom 10 percent of each sector had to be replaced or reformed. According to the newspaper, Wang applied the same ranking to vendors at the night market run by the Bund Finance Center, Fosun's headquarters complex.[3] Wang described the group's planning method as "1+2+7+endgame thinking": a one-year plan and budget, a three-year strategic plan, a ten-year vision and a view of where each industry would end up.[3]

Asked which companies Fosun modelled itself on, Wang said it had studied Berkshire Hathaway, GE and Hutchison Whampoa. He added that as an "innovation-driven global family consumption industry group" it now had no direct benchmark, saying: "We should just be ourselves." Wang described himself as an "enterprise worker".[3] In 2012 he told Harvard Business Review China that management should combine firmness with flexibility, likening it to tai chi, which he said only people practised in reverse thinking could do well.[15]

Wang's early speeches put weight on corporate social responsibility reporting. In 2010 he said a company should publish two reports, one on its economic and financial performance and one on social responsibility and sustainability. He summed up Fosun's values in 16 characters meaning "gratitude to others, restraint towards oneself, effort in one's work, care for things".[12]

Major deals and strategic decisions

Most of the large transactions in Wang's executive years were made by the group as a whole, not by him personally. Fosun's filings and statements record the following during his time as president and chief executive.

  • Club Med (2010): Wang described the investment in the French resort operator as taken during the European debt crisis.[12] By the end of 2016 the group held an effective 86.57 percent of Club Med.[20]
  • Peak Reinsurance (to 2018): Wang chaired the Hong Kong reinsurer until July 27, 2018, when Li Tao replaced him. He stayed on as a non-executive director. Peak Re's chief executive, Franz Josef Hahn, thanked him for his contribution as chairman.[27]
  • Fidelidade, Multicare and Cares (2014): Wang joined the boards of these Portuguese insurers after their acquisition. The group held 84.9861 percent of Fidelidade by the end of 2016.[18][20]
  • Ironshore (2015 to 2017): the group acquired all of the specialty insurer, and in May 2017, shortly after Wang became chief executive, sold it to Liberty Mutual for US$2.94 billion.[20][5]
  • Gland Pharma and St Hubert (2017): through Fosun Pharma, the group took a controlling stake in the Indian generic drug maker Gland Pharma. It also bought stakes in the French health food company St Hubert.[5]
  • Lanvin and Wolford (2018): the group agreed in February 2018 to buy a majority stake in the French fashion house Lanvin, completing the deal in early April 2018. In March 2018 it agreed to buy a majority of the Austrian hosiery maker Wolford.[21]
  • Fosun Tourism Group listing (December 2018): the tourism arm was spun off and listed in Hong Kong.[21]
  • Management reshuffle (February 2020): Wang moved from chief executive to co-chairman and day-to-day management passed to two co-chief executives.[22]

Financial and market performance

The table below shows the company's reported group results for the years around Wang's time as chief executive. Figures are in renminbi.

Year Revenue Profit attributable to owners of the parent Source
2016 RMB73.97 billion RMB10.27 billion [5]
2017 RMB88.03 billion RMB13.16 billion [5]
2018 RMB109.35 billion (restated) RMB13.41 billion [1]
2019 RMB142.98 billion RMB14.80 billion [1]

Earnings per share rose from RMB1.19 in 2016 to RMB1.53 in 2017, and were RMB1.73 in 2019.[5][1] National Business Daily reported in September 2020 that the company's share price had trended downward since late 2017. Its market capitalisation was about HK$75.9 billion, with a price-to-book ratio of 0.58, and the newspaper reported that some investors had criticised the group's portfolio as complex and its acquisitions as poorly connected.[3]

Remuneration and shareholding

Wang Qunbin's reported total remuneration, excluding share award expenses, was RMB11.43 million in 2017, RMB10.36 million in 2018 and RMB9.56 million in 2019.[5][1] It was RMB10.49 million in 2024 and RMB32.92 million in 2025, the rise in 2025 coming mainly from a performance-related bonus of RMB27.25 million.[24] The company recorded no share award or option expense for him in 2024 or 2025.[24]

Wang's stake in Fosun International Holdings rose from 10 percent at the 2007 listing to 11.11 percent at the end of 2017, when the other holders were Guo and Liang, and to 14.71 percent by February 2020, when Guo held the remaining 85.29 percent.[13][5][22] As of June 30, 2026, Wang also held 704,000 shares of the listed company directly and 114,075 A shares of Fosun Pharma.[7] He and Guo, together with the group's holding companies, are parties to a non-competition undertaking given to the listed company.[24]

Board memberships and outside roles

Wang Qunbin has held board seats at many group companies, including Fosun Pharma, Sinopharm, Yuyuan, Henan Lingrui Pharmaceutical, Nanjing Nangang, Forte, Peak Reinsurance, Fidelidade, Multicare, Cares and Ironshore.[16][18][19] Wang resigned as a non-executive director of Sinopharm in March 2019.[21] By February 2020 the company described his directorships of Fosun Pharma, Sinopharm, Yuyuan and Henan Lingrui as past roles.[22] In 2019 Wang stepped down from the company's remuneration and nomination committees, which the company said was to improve the committees' independence.[1]

His outside positions have included chairman, and later honorary chairman, of the Shanghai Biopharmaceutics Industry Association. He has also been vice chairman of the China Pharmaceutical Industry Association, chairman and later honorary chairman of the Huzhou Chamber of Commerce in Shanghai, and vice chairman of the China Chamber of International Commerce.[2][16][14] In May 2026 Fudan University's School of Life Sciences appointed him a development adviser at the centenary of its life sciences discipline.[9]

Personal life

Wang Qunbin lives in Shanghai.[8] Wang rarely speaks publicly about his personal life. National Business Daily's interviewer noted in 2020 that he was reluctant to discuss either his own circumstances or the company's history.[3]

Philanthropy

In 2010 Wang said the group's giving included donations to the Youth Business China programme, which supports young entrepreneurs, and to a foundation helping farmers and graduates start businesses. He also described the "Xingguangyao" plan with 16 private companies, under which 10 percent of profits were to go to supporting private enterprise and public causes.[12] At Fudan's life sciences centenary in May 2026, the Shanghai Fosun Foundation and alumni connected to the group made a donation to the university to support education. In his speech as an alumni representative, Wang said the group's 34 years had been "a practice of continuous evolution".[9]

Recognition

  • 2004: named one of the "Top Ten Professional Managers in China Pharmaceutical Industry"[2]
  • 2007: accredited for the State Council's special allowance for outstanding technical experts[2]
  • 2009: Young Global Leader, World Economic Forum[4]
  • Fourth Technology Innovation Prize of China Outstanding Youth; named in the Chinese pharmaceutical industry's "60 Years, 60 People"[4]
  • Named one of "The Best-Performing CEOs in the World" and later one of "China's 50 Top-performing Corporate Leaders" by Harvard Business Review[16][14]
  • 2014: Asia Pacific Outstanding Entrepreneur Award, Enterprise Asia; "Best Asian Corporate Director", Corporate Governance Asia[14]
  • 2016: Insurance Business "Hot 100"[19]

See also

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 <ref>"Annual Report 2019".Fosun International Limited.2020.Retrieved October 29, 2026.</ref>
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 <ref>"Annual Report 2009".Fosun International Limited.2010.Retrieved October 29, 2026.</ref>
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 <ref>Zhang Xiaoqing."资产"眼花缭乱"？汪群斌解惑复星：创新驱动 迈向深度产业运营".September 21, 2020.Retrieved October 29, 2026.</ref>
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 <ref>"Annual Report 2010".Fosun International Limited.2011.Retrieved October 29, 2026.</ref>
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 <ref>"Annual Report 2017".Fosun International Limited.2018.Retrieved October 29, 2026.</ref>
  6. ↑ 6.0 6.1 <ref>Xu Jinzhong."复星国际管理层亮相电话会 郭广昌谈变阵旨在提升产业运营水平".February 24, 2020.Retrieved October 29, 2026.</ref>
  7. ↑ 7.0 7.1 7.2 7.3 <ref>"Interim Report 2026".Fosun International Limited.September 2026.Retrieved October 29, 2026.</ref>
  8. ↑ 8.0 8.1 8.2 <ref>"Wang Qunbin".Forbes.April 5, 2021.Retrieved October 29, 2026.</ref>
  9. ↑ 9.0 9.1 9.2 <ref>"创新研发 加速成果落地全球市场｜复星周报20260530".Sina Finance.May 30, 2026.Retrieved October 29, 2026.</ref>
  10. ↑ <ref>"Management Team".Fosun International.Retrieved October 29, 2026.</ref>
  11. ↑ 11.0 11.1 11.2 <ref>"复星集团CEO梁信军深夜裸辞 郭广昌致信全体员工谈高层变动".March 29, 2017.Retrieved October 29, 2026.</ref>
  12. ↑ 12.0 12.1 12.2 12.3 12.4 <ref>"汪群斌：复星借金融危机加快国际化".Sohu Finance.November 25, 2010.Retrieved October 29, 2026.</ref>
  13. ↑ 13.0 13.1 13.2 <ref>"Annual Report 2007".Fosun International Limited.2008.Retrieved October 29, 2026.</ref>
  14. ↑ 14.0 14.1 14.2 14.3 <ref>"Annual Report 2015".Fosun International Limited.2016.Retrieved October 29, 2026.</ref>
  15. ↑ 15.0 15.1 15.2 <ref>Wang Feng."复星集团总裁汪群斌：受益对标管理".Harvard Business Review China.September 26, 2012.Retrieved October 29, 2026.</ref>
  16. ↑ 16.0 16.1 16.2 16.3 16.4 <ref>"Annual Report 2013".Fosun International Limited.2014.Retrieved October 29, 2026.</ref>
  17. ↑ <ref>Andrew Tjaardstra."Insurance Insight Q+A: Wang Qunbin, Fosun International".May 13, 2013.Retrieved October 29, 2026.</ref>
  18. ↑ 18.0 18.1 18.2 <ref>"Annual Report 2014".Fosun International Limited.2015.Retrieved October 29, 2026.</ref>
  19. ↑ 19.0 19.1 19.2 <ref>"Wang Qunbin".February 1, 2016.Retrieved October 29, 2026.</ref>
  20. ↑ 20.0 20.1 20.2 20.3 <ref>"Annual Report 2016".Fosun International Limited.2017.Retrieved October 29, 2026.</ref>
  21. ↑ 21.0 21.1 21.2 21.3 <ref>"Annual Report 2018".Fosun International Limited.2019.Retrieved October 29, 2026.</ref>
  22. ↑ 22.0 22.1 22.2 22.3 <ref>"Change of directors and executive positions and change of the composition of board committees".Fosun International Limited, via Hong Kong Exchanges and Clearing.February 21, 2020.Retrieved October 29, 2026.</ref>
  23. ↑ <ref>"复星国际高层大调整：陈启宇、徐晓亮升任联席CEO".Winshang, from Guandian Real Estate.February 22, 2020.Retrieved October 29, 2026.</ref>
  24. ↑ 24.0 24.1 24.2 24.3 24.4 <ref>"Annual Report 2025".Fosun International Limited.2026.Retrieved October 29, 2026.</ref>
  25. ↑ <ref>"复星国际续签汇丰中国战略合作协议，夯实全球化发展金融支撑".PEdaily.April 13, 2026.Retrieved October 29, 2026.</ref>
  26. ↑ <ref>"Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel".PR Newswire, via Webull.August 31, 2026.Retrieved October 29, 2026.</ref>
  27. ↑ <ref>"Peak Re appoints Fosun Insurance CEO Li Tao as Chairman of its Board".August 15, 2018.Retrieved October 29, 2026.</ref>
Retrieved from "https://ceo.wiki/index.php?title=Wang_Qunbin&oldid=9386"